The impact of meals on a probiotic during transit through a model of the human upper gastrointestinal tract

2011 ◽  
Vol 2 (4) ◽  
pp. 295-303 ◽  
Author(s):  
T. Tompkins ◽  
I. Mainville ◽  
Y. Arcand

Commercial literature on various probiotic products suggests that they can be taken before meals, during meals or after meals or even without meals. This has led to serious confusion for the industry and the consumer. The objective of our study was to examine the impact of the time of administration with respect to mealtime and the impact of the buffering capacity of the food on the survival of probiotic microbes during gastrointestinal transit. We used an in vitro Digestive System (IViDiS) model of the upper gastrointestinal tract to examine the survival of a commercial multi-strain probiotic, ProtecFlor®. This product, in a capsule form, contains four different microbes: two lactobacilli (Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011), Bifidobacterium longum R0175 and Saccharomyces cerevisiae boulardii. Enumeration during and after transit of the stomach and duodenal models showed that survival of all the bacteria in the product was best when given with a meal or 30 minutes before a meal (cooked oatmeal with milk). Probiotics given 30 minutes after the meal did not survive in high numbers. Survival in milk with 1% milk fat and oatmeal-milk gruel were significantly better than apple juice or spring water. S. boulardii was not affected by time of meal or the buffering capacity of the meal. The protein content of the meal was probably not as important for the survival of the bacteria as the fat content. We conclude that ideally, non-enteric coated bacterial probiotic products should be taken with or just prior to a meal containing some fats.

2009 ◽  
Vol 136 (5) ◽  
pp. A-781 ◽  
Author(s):  
Maria C. Bucur ◽  
Whitney Michalek ◽  
Richard McCallum ◽  
Kenneth L. Koch ◽  
Michael D. Sitrin ◽  
...  

2018 ◽  
Vol 9 (11) ◽  
pp. 5868-5879 ◽  
Author(s):  
Martín Sebastián Marcial-Coba ◽  
Tomasz Cieplak ◽  
Thiago Barbosa Cahú ◽  
Andreas Blennow ◽  
Susanne Knøchel ◽  
...  

Microencapsulated and subsequently freeze-dried cells showed acceptable storage stability and enhanced survival during in vitro upper gastrointestinal tract passage.


Medicina ◽  
2020 ◽  
Vol 56 (7) ◽  
pp. 363
Author(s):  
Lubomir Mihalkanin ◽  
Branislav Stancak

Background and objectives: Although treatment with novel oral non-vitamin K antagonist 3anticoagulants (NOACs) is associated with an overall decrease in hemorrhagic complications compared to warfarin, the incidence of gastrointestinal bleeding remains contradictory. Materials and Methods: After the exclusion of patients with pre-existing pathological lesions in the upper gastrointestinal tract (GIT) on esophageal-gastroduodenoscopy (EGD) at entry, a cohort of 80 patients (mean age of 74.8 ± 2.0 years) was randomly divided into four equivalent groups, treated with dabigatran, rivaroxaban, apixaban, or warfarin. Patients were prospectively followed up for three months of treatment, with a focus on anamnestic and endoscopic signs of bleeding. In addition, bleeding risk factors were evaluated. Results: In none of the patients treated with warfarin or NOACs was any serious or clinically significant bleeding recorded within the follow-up period. The incidence of clinical bleeding and endoscopically detected bleeding in the upper GT after three months of treatment was not statistically different among groups (χ2 = 2.8458; p = 0.41608). The presence of Helicobacter pylori (HP) was a risk factor for upper GIT bleeding (p < 0.05), while the use of proton pump inhibitors (PPIs) was a protective factor (p = 0.206; Spearman’s correlation coefficient = 0.205). We did not record any post-biopsy continued bleeding. Conclusions: No significant GIT bleeding was found in any of the treatment groups, so we consider it beneficial to perform routine EGD before the initiation of any anticoagulant therapy in patients with an increased risk of upper GIT bleeding. Detection and eradication of HP as well as preventive PPI treatment may mitigate the occurrence of endoscopic bleeding. Endoscopic biopsy during the NOAC treatment is safe.


2010 ◽  
Vol 58 (17) ◽  
pp. 9847-9854 ◽  
Author(s):  
Elizabeth A. Tydeman ◽  
Mary L. Parker ◽  
Martin S. J. Wickham ◽  
Gillian T. Rich ◽  
Richard M. Faulks ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document